Sanne Schagen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7254333/publications.pdf

Version: 2024-02-01

118 papers	8,248 citations	66234 42 h-index	54797 84 g-index
125 all docs	125 docs citations	125 times ranked	5873 citing authors

#	Article	IF	Citations
1	International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncology, The, 2011, 12, 703-708.	5.1	717
2	Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy. Journal of the National Cancer Institute, 1998, 90, 210-218.	3.0	698
3	Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. , 1999, 85, 640-650.		552
4	Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy. Journal of Clinical Oncology, 2012, 30, 1080-1086.	0.8	408
5	Clinical characteristics, pathophysiology, and management of noncentral nervous system cancerâ€related cognitive impairment in adults. Ca-A Cancer Journal for Clinicians, 2015, 65, 123-138.	157.7	368
6	Chemotherapy-Related Cognitive Dysfunction. Current Neurology and Neuroscience Reports, 2012, 12, 267-275.	2.0	302
7	Response Perseveration and Ventral Prefrontal Sensitivity to Reward and Punishment in Male Problem Gamblers and Smokers. Neuropsychopharmacology, 2009, 34, 1027-1038.	2.8	285
8	Change in Cognitive Function After Chemotherapy: a Prospective Longitudinal Study in Breast Cancer Patients. Journal of the National Cancer Institute, 2006, 98, 1742-1745.	3.0	266
9	Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain Mapping, 2011, 32, 1206-1219.	1.9	243
10	Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 2010, 28, 1294-1300.	0.8	227
11	Late effects of highâ€dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Human Brain Mapping, 2012, 33, 2971-2983.	1.9	218
12	Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behavioural Brain Research, 2008, 186, 168-175.	1.2	209
13	Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Research and Treatment, 2012, 132, 1099-1106.	1.1	145
14	Similar hyporesponsiveness of the dorsomedial prefrontal cortex in problem gamblers and heavy smokers during an inhibitory control task. Drug and Alcohol Dependence, 2012, 121, 81-89.	1.6	141
15	Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behavioural Brain Research, 2009, 201, 279-284.	1.2	126
16	Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. Journal of Pain and Symptom Management, 2015, 50, 830-841.	0.6	125
17	Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. Journal of Neuro-Oncology, 2001, 51, 159-165.	1.4	113
18	Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. Acta OncolÃ³gica, 2009, 48, 76-85.	0.8	110

#	Article	IF	Citations
19	Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta OncolÃ³gica, 2008, 47, 63-70.	0.8	107
20	Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment â€" The role of fatigue. NeuroImage: Clinical, 2015, 7, 547-554.	1.4	104
21	Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Human Brain Mapping, 2014, 35, 889-899.	1.9	98
22	Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Research, 2018, 20, 135.	2.2	94
23	Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behavioural Brain Research, 2010, 207, 265-272.	1.2	93
24	Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675). Journal of Thoracic Oncology, 2021, 16, 840-849.	0.5	78
25	Amsterdam short-term memory test: A new procedure for the detection of feigned memory deficits. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 43-51.	0.8	77
26	Electrophysiological Correlates of Information Processing in Breast-Cancer Patients Treated With Adjuvant Chemotherapy. Breast Cancer Research and Treatment, 2005, 94, 53-61.	1.1	77
27	Effects of High-Dose and Conventional-Dose Adjuvant Chemotherapy on Long-Term Cognitive Sequelae in Patients with Breast Cancer: An Electrophysiologic Study. Clinical Breast Cancer, 2006, 7, 67-78.	1.1	76
28	International Cognition and Cancer Task Force Recommendations for Neuroimaging Methods in the Study of Cognitive Impairment in Non-CNS Cancer Patients. Journal of the National Cancer Institute, 2018, 110, 223-231.	3.0	71
29	Neurotoxicity in breast cancer survivors â‰¥10Âyears post-treatment is dependent on treatment type. Brain Imaging and Behavior, 2015, 9, 275-284.	1.1	69
30	Persistent Neurocognitive Problems After Adjuvant Chemotherapy for Breast Cancer. Clinical Breast Cancer, 2008, 8, 80-87.	1.1	61
31	Changes in brain white matter integrity after systemic treatment for breast cancer: a prospective longitudinal study. Brain Imaging and Behavior, 2018, 12, 324-334.	1.1	60
32	Information about chemotherapyâ€associated cognitive problems contributes to cognitive problems in cancer patients. Psycho-Oncology, 2012, 21, 1132-1135.	1.0	59
33	Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. Critical Reviews in Oncology/Hematology, 2013, 88, 87-101.	2.0	59
34	Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studies. Psycho-Oncology, 2021, 30, 635-648.	1.0	58
35	Reliability and validity of a self-administered tool for online neuropsychological testing: The Amsterdam Cognition Scan. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 253-273.	0.8	55
36	Balance between innate versus adaptive immune system and the risk of dementia: a population-based cohort study. Journal of Neuroinflammation, 2019, 16, 68.	3.1	55

#	Article	IF	Citations
37	Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer. Menopause, 2015, 22, 17-25.	0.8	54
38	The influence of priming and preâ€existing knowledge of chemotherapyâ€associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psycho-Oncology, 2009, 18, 674-678.	1.0	53
39	Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Human Brain Mapping, 2015, 36, 4638-4647.	1.9	53
40	Cognitive impact of cytotoxic agents in mice. Psychopharmacology, 2015, 232, 17-37.	1.5	53
41	Cancer and dementia: Two sides of the same coin?. European Journal of Clinical Investigation, 2018, 48, e13019.	1.7	52
42	Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?. Nature Reviews Clinical Oncology, 2015, 12, 597-606.	12.5	51
43	ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clinical Neurophysiology, 2008, 119, 533-541.	0.7	50
44	Cognitive dysfunction in people with cancer. Lancet Oncology, The, 2007, 8, 852-853.	5.1	47
45	Online cognition: factors facilitating reliable online neuropsychological test results. Clinical Neuropsychologist, 2017, 31, 59-84.	1.5	46
46	Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. Brain Research Bulletin, 2010, 81, 472-476.	1.4	45
47	Cognitive Impairment in a Subset of Breast Cancer Patients After Systemic Therapyâ€"Results From a Longitudinal Study. Journal of Pain and Symptom Management, 2016, 52, 560-569.e1.	0.6	44
48	Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders. Neuroscience and Biobehavioral Reviews, 2019, 105, 288-304.	2.9	42
49	Chemotherapy-related changes in cognitive functioning. European Journal of Cancer, Supplement, 2013, 11, 225-232.	2.2	41
50	Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS ONE, 2017, 12, e0171724.	1.1	41
51	ADHD and maturation of brain white matter: A DTI study in medication naive children and adults. NeuroImage: Clinical, 2018, 17, 53-59.	1.4	40
52	Functional MRI studies in non-CNS cancers. Brain Imaging and Behavior, 2013, 7, 388-408.	1.1	39
53	Prevalence of Cerebral Small-Vessel Disease in Long-Term Breast Cancer Survivors Exposed to Both Adjuvant Radiotherapy and Chemotherapy. Journal of Clinical Oncology, 2015, 33, 588-593.	0.8	38
54	Cancer-related cognitive problems at work: experiences of survivors and professionals. Journal of Cancer Survivorship, 2020, 14, 168-178.	1.5	37

#	Article	IF	Citations
55	Neurobiological changes by cytotoxic agents in mice. Behavioural Brain Research, 2016, 299, 19-26.	1.2	36
56	Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?. Life Sciences, 2013, 93, 581-588.	2.0	34
57	Reliable change in neuropsychological assessment of breast cancer survivors. Psycho-Oncology, 2016, 25, 43-50.	1.0	34
58	The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy. Psycho-Oncology, 2010, 19, 415-422.	1.0	32
59	Cancer-related cognitive impairment and patientsâ€™ ability to work: a current perspective. Current Opinion in Supportive and Palliative Care, 2017, 11, 19-23.	0.5	32
60	Interventions for cognitive problems in adults with brain cancer: A narrative review. European Journal of Cancer Care, 2019, 28, e13088.	0.7	31
61	Online Self-Administered Cognitive Testing Using the Amsterdam Cognition Scan: Establishing Psychometric Properties and Normative Data. Journal of Medical Internet Research, 2018, 20, e192.	2.1	31
62	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. Nature Reviews Neurology, 2022, 18, 173-185.	4.9	31
63	Broadening the cancer and cognition landscape: the role of self-regulatory challenges. Psycho-Oncology, 2014, 23, 1-8.	1.0	29
64	Very Late Treatment-Related Alterations in Brain Function of Breast Cancer Survivors. Journal of the International Neuropsychological Society, 2015, 21, 50-61.	1.2	29
65	Ascertainment of cancer in longitudinal research: The concordance between the Rotterdam Study and the Netherlands Cancer Registry. International Journal of Cancer, 2020, 147, 633-640.	2.3	25
66	Trajectories of Cognitive and Motor Function Between Ages 45 and 90 Years: A Population-Based Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 297-306.	1.7	24
67	Genetic imaging consortium for addiction medicine. Progress in Brain Research, 2016, 224, 203-223.	0.9	22
68	Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. European Journal of Cancer, 2011, 47, 2531-2536.	1.3	21
69	Effect of physical exercise on cognitive function and brain measures after chemotherapy in patients with breast cancer (PAM study): protocol of a randomised controlled trial. BMJ Open, 2019, 9, e028117.	0.8	21
70	Hippocampusâ€"Related Cognitive and Affective Impairments in Patients With Breast Cancerâ€"A Systematic Review. Frontiers in Oncology, 2020, 10, 147.	1.3	20
71	Cognitive impairment and associated loss in brain white microstructure in aircrew members exposed to engine oil fumes. Brain Imaging and Behavior, 2016, 10, 437-444.	1.1	19
72	Neurocognitive function of lymphoma patients after treatment with chemotherapy. Acta OncolÃ³gica, 2016, 55, 1121-1125.	0.8	18

#	Article	IF	Citations
73	Measuring decline in white matter integrity after systemic treatment for breast cancer: omitting skeletonization enhances sensitivity. Brain Imaging and Behavior, 2021, 15, 1191-1200.	1.1	18
74	Negative words enhance recognition in nonclinical high dissociators: An fMRI study. NeuroImage, 2007, 37, 323-334.	2.1	17
75	Age-dependent effects of acute methylphenidate on amygdala reactivity in stimulant treatment-naive patients with Attention Deficit/Hyperactivity Disorder. Psychiatry Research - Neuroimaging, 2017, 269, 36-42.	0.9	16
76	Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study. Journal of Cancer Survivorship, 2020, 14, 158-167.	1.5	16
77	Trajectories of Cognitive Function Prior to Cancer Diagnosis: A Population-Based Study. Journal of the National Cancer Institute, 2020, 112, 480-488.	3.0	14
78	Mild Cognitive Impairment and Dementia Show Contrasting Associations with Risk of Cancer. Neuroepidemiology, 2018, 50, 207-215.	1.1	13
79	Self-perceived cognitive functioning and quality of life among cancer survivors: results from the PROFILES registry. Journal of Cancer Survivorship, 2022, 16, 303-313.	1.5	13
80	Using fMRI to Investigate Memory in Young Children Born Small for Gestational Age. PLoS ONE, 2015, 10, e0129721.	1.1	12
81	Internet-based cognitive rehabilitation for WORking Cancer survivors (i-WORC): study protocol of a randomized controlled trial. Trials, 2020, 21, 664.	0.7	12
82	Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2021, 39, 3908-3917.	0.8	12
83	Alzheimerâ€™s disease as a multistage process: an analysis from a population-based cohort study. Aging, 2019, 11, 1163-1176.	1.4	12
84	Brain Hyperconnectivity >10 Years After Cisplatin-Based Chemotherapy for Testicular Cancer. Brain Connectivity, 2018, 8, 398-406.	0.8	11
85	Multi-center reproducibility of structural, diffusion tensor, and resting state functional magnetic resonance imaging measures. Neuroradiology, 2018, 60, 617-634.	1.1	10
86	Measuring Clinical, Biological, and Behavioral Variables to Elucidate Trajectories of Patient-Reported Outcomes: The PROFILES Registry. Journal of the National Cancer Institute, 2022, 114, 800-807.	3.0	10
87	Visualization formats of patient-reported outcome measures in clinical practice: a systematic review about preferences and interpretation accuracy. Journal of Patient-Reported Outcomes, 2022, 6, 18.	0.9	10
88	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Research Protocols, 2021, 10, e24414.	0.5	9
89	FAst Segmentation Through SURface Fairing (FASTSURF): A novel semi-automatic hippocampus segmentation method. PLoS ONE, 2019, 14, e0210641.	1.1	8
90	Pathology-confirmed versus non pathology-confirmed cancer diagnoses: incidence, participant characteristics, and survival. European Journal of Epidemiology, 2020, 35, 557-565.	2.5	8

#	Article	IF	Citations
91	How to Correct for Computer Experience in Online Cognitive Testing?. Assessment, 2021, 28, 1247-1255.	1.9	8
92	Fatigue and resting-state functional brain networks in breast cancer patients treated with chemotherapy. Breast Cancer Research and Treatment, 2021, 189, 787-796.	1.1	8
93	Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?. Clinical Breast Cancer, 2022, 22, 191-199.	1.1	8
94	Late effects of adjuvant chemotherapy for breast cancer on fine motor function. Psycho-Oncology, 2015, 24, 1799-1807.	1.0	7
95	Editorial: Post-traumatic Stress as the Primary Cause for Cognitive Declineâ€"Not the Whole Story, and Perhaps No Story at All. Journal of the National Cancer Institute, 2017, 109, .	3.0	7
96	Long-term effects of adjuvant treatment for breast cancer on carotid plaques and brain perfusion. Breast Cancer Research and Treatment, 2021, 186, 167-176.	1.1	7
97	Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: protocol for a feasibility study. BMJ Open, 2020, 10, e038312.	0.8	6
98	Preventing adverse information effects on health outcomes: A self-affirmation intervention reduced information-induced cognitive decline in gastrointestinal cancer patients. Social Science and Medicine, 2019, 226, 47-55.	1.8	5
99	Trajectories of Cognitive Symptoms in Sick-Listed Cancer Survivors. Cancers, 2021, 13, 2444.	1.7	5
100	Systemically Treated Breast Cancer Patients and Controls: An Evaluation of the Presence of Noncredible Performance. Journal of the International Neuropsychological Society, 2014, 20, 357-369.	1.2	4
101	Trajectories of cognitive symptoms and associated factors in cancer survivors after return to work: an 18-month longitudinal cohort study. Journal of Cancer Survivorship, 2023, 17, 290-299.	1.5	4
102	Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI. Neuro-Oncology, 0, , .	0.6	4
103	Binary classification threatens the validity of cognitive impairment detection.. Neuropsychology, 2023, 37, 344-350.	1.0	4
104	Neuropsychological test performance and self-reported cognitive functioning associated with work-related outcomes in occupationally active cancer survivors with cognitive complaints. Journal of Cancer Survivorship, 0, , .	1.5	4
105	Association Between the Tumor Marker Carcinoembryonic Antigen and the Risk of Dementia. Journal of Alzheimer's Disease, 2020, 76, 1-7.	1.2	3
106	Higher Plasma Amyloid-Î² Levels Are Associated with a Higher Risk of Cancer: A Population-Based Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1993-2001.	1.1	3
107	Brain structure prior to non-central nervous system cancer diagnosis: A population-based cohort study. NeuroImage: Clinical, 2020, 28, 102466.	1.4	3
108	Temporal Dynamics of Resting-state Functional Networks and Cognitive Functioning following Systemic Treatment for Breast Cancer. Brain Imaging and Behavior, 2022, 16, 1927-1937.	1.1	3

#	Article	IF	Citations
109	Aortic Arch Calcification and the Risk of Cancer: A Population-Based Cohort Study. Frontiers in Oncology, 2020, 10, 1700.	1.3	2
110	Change in cognition before and after nonâ€central nervous system cancer diagnosis: A populationâ€based cohort study. Psycho-Oncology, 2021, 30, 1699-1710.	1.0	2
111	Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?. Journal of Thoracic Oncology, 2021, 16, e42-e45.	0.5	2
112	Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment. Cancers, 2021, 13, 5675.	1.7	2
113	The Effects of Being Informed About Chemotherapy-Related Cognitive Symptoms With And Without Self-Affirmation on Perceived Cognitive Symptoms of Breast Cancer Patients: A Randomized Prospective, Longitudinal Study. Clinical Breast Cancer, 2022, 22, 439-454.	1.1	2
114	Response: Re: Neurocognitive Functioning in Adult Survivors of Childhood Noncentral Nervous System Cancers. Journal of the National Cancer Institute, 2011, 103, 607-608.	3.0	1
115	Computational Modeling of Neuropsychological Test Performance to Disentangle Impaired Cognitive Processes in Cancer Patients. Journal of the National Cancer Institute, 2021, 113, 99-102.	3.0	1
116	Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: A randomized controlled trial (PAM study).. Journal of Clinical Oncology, 2021, 39, 12015-12015.	0.8	1
117	Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675). Journal of Thoracic Oncology, 2021, 16, e63-e65.	0.5	1
118	Cognitive Rehabilitation in Patients with Non-Central Nervous System Cancers and Brain Tumors. , 2020, , 221-254.		1